EUVIMEDEUVIMED entdecken
Crossref

Pharmacodynamic, pharmacokinetic and rat brain receptor occupancy profile of NLX-112, a highly selective 5-HT1A receptor biased agonist

Ronan Y Depoortère, Andrew C McCreary, Benjamin Vidal, Mark A Varney, Luc Zimmer, Adrian Newman-Tancredi

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-024-03323-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Ronan Y Depoortère und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neurolixis SAS, 2 Rue Georges Charpak, 81100, Castres, France. Hauptthemen laut MEDLINE: Receptor, Serotonin, 5-HT1A, Serotonin 5-HT1 Receptor Agonists, Brain, Pyridines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Agence Nationale de la Recherche, Université Claude Bernard Lyon 1, Michael J. Fox Foundation for Parkinson's Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NLX-112 (i.e., F13640, befiradol) exhibits nanomolar affinity, exceptional selectivity and full agonist efficacy at serotonin 5-HT1A receptors. NLX-112 shows efficacy in rat, marmoset and macaque models of L-DOPA induced dyskinesia (LID) in Parkinson's disease and has shown clinical efficacy in a Phase 2a proof-of-concept study for this indication. Here we investigated, in rats, its pharmacodynamic, pharmacokinetic (PK) and brain 5-HT1A receptor occupancy profiles, and its PK properties in the absence and presence of L-DOPA. Total and free NLX-112 exposure in plasma, CSF and striatal ECF was dose-proportional over the range tested (0.04, 0.16 and 0.63 mg/kg i.p.). NLX-112 exposure increased rapidly (Tmax 0.25-0.5h) and exhibited approximately threefold longer half-life in brain than in plasma (1.1 and 3.6h, respectively). At a pharmacologically relevant dose of 0.16 mg/kg i.p., previously shown to elicit anti-LID activity in parkinsonian rats, brain concentration of NLX-112 was 51-63 ng/g from 0.15 to 1h. In microPET imaging experiments, NLX-112 showed dose-dependent reduction of 18F-F13640 (i.e., 18F-NLX-112) brain 5-HT1A receptor labeling in cingulate cortex and striatum, regions associated with motor control and mood, with almost complete inhibition of labeling at the dose of 0.63 mg/kg i.p.. Co-administration of L-DOPA (6 mg/kg s.c., a dose used to elicit LID in parkinsonian rats) together with NLX-112 (0.16 mg/kg i.p.) did not modify PK parameters in rat plasma and brain of either NLX-112 or L-DOPA. Here, we demonstrate that NLX-112's profile is compatible with 'druggable' parameters for CNS indications, and the results provide measures of brain concentrations and 5-HT1A receptor binding parameters relevant to the anti-dyskinetic activity of the compound.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Serotonin, 5-HT1ASerotonin 5-HT1 Receptor AgonistsBrainPyridinesAnimalsMaleLevodopaRats, Sprague-DawleyRatsAntiparkinson AgentsPiperazinesPiperidines

Stichwörter der Autor:innen

5-HT1A receptorsDyskinesiaL-DOPANLX-112Parkison’s diseasePharmacokineticsRat

Substanzen

Receptor, Serotonin, 5-HT1ASerotonin 5-HT1 Receptor AgonistsbefiradolLevodopaPyridinesAntiparkinson AgentsPiperazinesPiperidines

Autor:innen und Institutionen

  • Neurolixis SAS, 2 Rue Georges Charpak, 81100, Castres, France.
  • Brains On-Line, Groningen, Netherlands.
  • GW Pharmaceuticals, Cambridge, UK.
  • Université Claude Bernard Lyon 1, Lyon Neuroscience Research Center, CNRS, INSERM, CERMEP-Imaging Platform, Bron, France.
  • Hospices Civils de Lyon, Lyon, France.
  • Neurolixis SAS, 2 Rue Georges Charpak, 81100, Castres, France. anewmantancredi@neurolixis.com.

Förderung

  • Agence Nationale de la Recherche
  • Université Claude Bernard Lyon 1
  • Michael J. Fox Foundation for Parkinson's Research
  • Neurolixis

Zitieren

APA

Depoortère, R. Y., McCreary, A. C., Vidal, B., Varney, M. A., Zimmer, L., & Newman-Tancredi, A. (2025). Pharmacodynamic, pharmacokinetic and rat brain receptor occupancy profile of NLX-112, a highly selective 5-HT1A receptor biased agonist. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03323-0

Vancouver

Depoortère RY, McCreary AC, Vidal B, Varney MA, Zimmer L, Newman-Tancredi A. Pharmacodynamic, pharmacokinetic and rat brain receptor occupancy profile of NLX-112, a highly selective 5-HT1A receptor biased agonist. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-024-03323-0

BibTeX
@article{Depoortre2025,
  author = {Depoortère, Ronan Y and McCreary, Andrew C and Vidal, Benjamin and Varney, Mark A and Zimmer, Luc and Newman-Tancredi, Adrian},
  title = {Pharmacodynamic, pharmacokinetic and rat brain receptor occupancy profile of NLX-112, a highly selective 5-HT1A receptor biased agonist},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-024-03323-0}
}
Kostenlos starten →